Yueming Hu, Ting Liu, Li Tian, Bohai Cao, Jinheng Xu
{"title":"Overexpression FARSB Reveals Poor Prognosis in Breast Cancer and is Correlated with Immunity.","authors":"Yueming Hu, Ting Liu, Li Tian, Bohai Cao, Jinheng Xu","doi":"10.1080/07357907.2025.2512379","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>FARSB is a β-regulatory subunit of phenylalanine tRNA synthetase. It is reported that FARSB was involved in cancer progression. However, the molecular function of FARSB in breast cancer was unclear. This study aimed to investigate the prognostic significance of FARSB expression and its relationship with immunity in breast cancer.</p><p><strong>Methods: </strong>Several databases, including TCGA, HPA, and UALCAN database, were applied to study FARSB mRNA and protein expression and its association with aggressiveness in breast cancer. We used immunohistochemical staining (IHC) to study FARSB expression in breast cancer and normal tissues. Chi square test was explored to study the correlation between FARSB expression and clinical features in breast cancer. Kaplan-Meier analysis and Cox regression were utilized to discuss the prognosis of breast cancer. Spearman analysis was applied to analyze the association between FARSB expression and immunity. We studied the correlation of FARSB with common breast cancer chemotherapeutic drugs. We conducted GO, KEGG, and GSEA enrichment analysis to study the molecular function of FARSB in breast cancer.</p><p><strong>Results: </strong>The TCGA database suggested that FARSB was increased in several cancers, including breast cancer. HPA and UALCAN databases suggested that FARSB protein expression was higher in breast cancer than normal tissues. IHC analysis also confirmed the higher expression of FARSB in breast cancer. FARSB expression had correlation with ER status and PR status. In TCGA database, FARSB expression was related to ER status, PR status, and PAM50. Overexpression FARSB had adverse prognosis, and Cox regression considered FARSB as a prognostic marker. Immunological analysis demonstrated that FARSB was linked with immune cell infiltration and immune checkpoints. High FARSB expression had low TIDE score. In addition, FARSB was linked to drugs, such as 5-fluorouracil, doxorubicin, gemcitabine, and paclitaxel. GSEA analysis suggested that FARSB was involved in the pathways, including cell cycle, aminoacyl TRNA biosynthesis, DNA replication, spliceosome, and mismatch repair.</p><p><strong>Conclusion: </strong>FARSB was highly expression at mRNA and protein level in breast cancer. Overexpression of FARSB had a poor prognosis in breast cancer. FARSB expression was associated with immunity and acted as a new target for cancer immunological therapy.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"326-336"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2025.2512379","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: FARSB is a β-regulatory subunit of phenylalanine tRNA synthetase. It is reported that FARSB was involved in cancer progression. However, the molecular function of FARSB in breast cancer was unclear. This study aimed to investigate the prognostic significance of FARSB expression and its relationship with immunity in breast cancer.
Methods: Several databases, including TCGA, HPA, and UALCAN database, were applied to study FARSB mRNA and protein expression and its association with aggressiveness in breast cancer. We used immunohistochemical staining (IHC) to study FARSB expression in breast cancer and normal tissues. Chi square test was explored to study the correlation between FARSB expression and clinical features in breast cancer. Kaplan-Meier analysis and Cox regression were utilized to discuss the prognosis of breast cancer. Spearman analysis was applied to analyze the association between FARSB expression and immunity. We studied the correlation of FARSB with common breast cancer chemotherapeutic drugs. We conducted GO, KEGG, and GSEA enrichment analysis to study the molecular function of FARSB in breast cancer.
Results: The TCGA database suggested that FARSB was increased in several cancers, including breast cancer. HPA and UALCAN databases suggested that FARSB protein expression was higher in breast cancer than normal tissues. IHC analysis also confirmed the higher expression of FARSB in breast cancer. FARSB expression had correlation with ER status and PR status. In TCGA database, FARSB expression was related to ER status, PR status, and PAM50. Overexpression FARSB had adverse prognosis, and Cox regression considered FARSB as a prognostic marker. Immunological analysis demonstrated that FARSB was linked with immune cell infiltration and immune checkpoints. High FARSB expression had low TIDE score. In addition, FARSB was linked to drugs, such as 5-fluorouracil, doxorubicin, gemcitabine, and paclitaxel. GSEA analysis suggested that FARSB was involved in the pathways, including cell cycle, aminoacyl TRNA biosynthesis, DNA replication, spliceosome, and mismatch repair.
Conclusion: FARSB was highly expression at mRNA and protein level in breast cancer. Overexpression of FARSB had a poor prognosis in breast cancer. FARSB expression was associated with immunity and acted as a new target for cancer immunological therapy.
期刊介绍：
Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
